Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2003
11/20/2003WO2003019136A3 Methods for inhibiting angiogenesis
11/20/2003WO2003016506A3 Secreted proteins
11/20/2003WO2003016468A3 Antagonistic anti-htnfsf13b human antibodies
11/20/2003WO2003016344A3 Use of lung carcinoma antigen
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003008444A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/20/2003WO2003004627B1 Novel human hepatoma lines, methods for obtaining same and uses thereof
11/20/2003WO2003004055A3 Nucleic acid adjuvants
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002101045A3 Vanilloid receptor-related nucleic acids and polypeptides
11/20/2003WO2002099116A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002088380A3 Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
11/20/2003WO2002086071A3 Cancer-testis antigens
11/20/2003WO2002083736A3 G-protein coupled receptor molecules and uses thereof
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002077234A3 Compositions and methods relating to colon specific genes and proteins
11/20/2003WO2002066501A3 PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
11/20/2003WO2002062368A8 Method of inducing a ctl response
11/20/2003WO2002060935A3 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
11/20/2003WO2002053189A3 Immunogenic complex
11/20/2003WO2002053092A8 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
11/20/2003WO2002038744A3 Proteases
11/20/2003WO2002034915A3 Preferred segments of neural thread protein and methods of using the same
11/20/2003WO2002033050A8 Methods and compositions for promoting the maturation of monocytes
11/20/2003WO2002008765A3 Basal cell markers in breast cancer and uses thereof
11/20/2003WO2001085664A8 Compounds and methods for regulating bacterial growth and pathogenesis
11/20/2003US20030216559 Medical diagnosis using polypeptide; amplification, determination, calibration; monitoring immunotherapy
11/20/2003US20030216546 Genetically engineered fusion proteins for use in diagnosis and treatment of cancer, viral infections, autoimmune and alloimmune diseases
11/20/2003US20030216544 Methods and reagents for diagnosis of autoantibodies
11/20/2003US20030216343 Expression vectors for stimulating an immune response and methods of using the same
11/20/2003US20030216342 Expression vectors for stimulating an immune response and methods of using the same
11/20/2003US20030216319 Selective suppression of autoimmune activity against an auto-antigen
11/20/2003US20030216306 Therapeutic uses of glandular kallikrein
11/20/2003US20030216288 Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215885 Using presence of antibody complex to diagnose inflammatory diseases; antiiflammatory agents; immunoassay
11/20/2003US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders
11/20/2003US20030215823 Uses of galanin GALR2 receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215820 Regulators of type-1tumor necrosis factor receptor and other cytokine receptor shedding
11/20/2003US20030215797 Vaccines and immunotherapeutics derived from the human immunodeficiency virus ( HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease
11/20/2003US20030215795 Highly infectious rubella virus DNA constructs and methods of production
11/20/2003US20030215793 Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
11/20/2003US20030215792 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptide
11/20/2003US20030215512 Stable glassy state powder formulations
11/20/2003US20030215497 Adjuvant composition and methods for its use
11/20/2003US20030215492 Administering a mammalian host for treating a disease caused by proliferation of eukaryotic cells a formulation containing a complex of lipid and a drug 7-ethyl-10-hydroxycamptothecin
11/20/2003US20030215469 Multicomponent meningococcal vaccine
11/20/2003US20030215468 Soluble recombinant botulinum toxin proteins
11/20/2003US20030215466 Which is incapable of reproduction within human cell lines; for treatment of human immunodeficency virus
11/20/2003US20030215464 Lipoprotein gene expression; point mutations; fusion proteins
11/20/2003US20030215463 Replication defective herpes virus vector has a deletion of at least a fragment of a UL29 gene that is replaced with a heterologous sequence encoding an antigen from a specific infectious disease agent
11/20/2003US20030215461 Immunogenic composition comprising adenyl cyclase-hemolysin protein, or portion thereof, strain of Bordetella chosen from B.pertussis, B.parapertussis or B.bronchiseptica, bacterial extract containing expression product of bordetella vrg genes
11/20/2003US20030215460 Methods and compositions for inducing an immune response
11/20/2003US20030215458 Comprise wilms' tumor suppressor gene(wt1) polynucleotide, polypeptide, antigen-presenting cell presenting WT1 polypeptide, antibody that specifically binds to or T cell that specifically reacts with WT1 polypeptide; immunotherapy
11/20/2003US20030215457 Comprising a nucleic acid, a polypeptide encoded by the nucleic acid, and a compound, preferably an antibody or fragment thereof, that binds to the polypeptide, preferably binding to the extracellular domain of LIV-1 polypeptide
11/20/2003US20030215452 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030215450 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/20/2003US20030215448 Compositions and methods for treating hyperimmune response in the eye
11/20/2003US20030215447 Produced by hybridoma cell line DSM ACC 2533
11/20/2003US20030215446 CATT-tetranucleotide repeat polymorphism at position-817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays
11/20/2003US20030215445 Concerns an 88 kDa glycoprotein growth factor ("GP88" or "PCDGF") and compositions and methods which affect the expression and biological activity of GP88; useful for diagnosis and treatment of diseases
11/20/2003US20030215444 And stimulate erythropoiesis; teatment of anemia
11/20/2003US20030215443 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/20/2003US20030215425 Epitope synchronization in antigen presenting cells
11/20/2003US20030215402 Porphyromonas gingivalis recombinant proteins and truncations
11/20/2003CA2492394A1 Induction of antigen specific immunologic tolerance
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2488968A1 Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy
11/20/2003CA2485999A1 Mucosal combination vaccines for bacterial meningitis
11/20/2003CA2485992A1 Mucosal vaccines with chitosan adjuvant and meningococcal antigens
11/20/2003CA2485655A1 Recombinant fowlpox virus
11/20/2003CA2485400A1 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2485363A1 Ferritin fusion proteins for use in vaccines and other applications
11/20/2003CA2485256A1 Pathogen vaccines and methods for using the same
11/20/2003CA2485120A1 Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
11/20/2003CA2484669A1 Brachyspira hyodysenteriae vaccine
11/20/2003CA2484645A1 Ebv vaccine using gp350 antigen
11/20/2003CA2484607A1 Methods and compositions for inducing an immune response
11/20/2003CA2484279A1 Improved polysaccharide and glycoconjugate vaccines
11/20/2003CA2484266A1 Cancer vaccines and methods of using the same
11/20/2003CA2462203A1 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/19/2003EP1362868A2 Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
11/19/2003EP1362597A1 Antigenic peptides derived from telomerase
11/19/2003EP1362596A2 Inhibitor of stem cell proliferation and uses thereof
11/19/2003EP1362109A2 Recombinant oligomeric protein complexes with enhanced immunogenic potential
11/19/2003EP1362106A2 Streptococcus pyogenes polypeptides and corresponding dna fragments
11/19/2003EP1362105A2 Anti-interferon-alpha antibodies
11/19/2003EP1362061A2 Antibodies that bind both bcma and taci
11/19/2003EP1362058A2 Comparative ligand mapping from mhc positive cells
11/19/2003EP1361898A2 Modulated release particles for aerosol delivery
11/19/2003EP1361893A1 Modified anti-egfr antibodies with reduced immunogenicity
11/19/2003EP1361892A1 Binding domain-immunoglobulin fusion proteins
11/19/2003EP1361891A2 Artificial fusion proteins with reduced immunogenicity
11/19/2003EP1361890A2 Influenza vaccine formulations for intradermal delivery
11/19/2003EP1361889A1 Novel vaccine
11/19/2003EP1361886A2 Methods and compositions for inhibiting hiv-coreceptor interactions
1 ... 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 ... 1823